Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 21 February 2018, 08:25 HKT/SGT
Share:
    

Source: Eisai
Eisai Certified in 2018 as Outstanding Health and Productivity Management Organization (White 500)

TOKYO, Feb 21, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been certified in 2018 as an Outstanding Health and Productivity Management Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry, who organizes the Certified Health and Productivity Management Organization Recognition Program in cooperation with Nippon Kenko Kaigi which consists of leaders of medical care associations, economic associations as well as municipalities.

Under the recognition program, the Nippon Kenko Kaigi examines large enterprises, small-medium enterprises and other organizations engaging in initiatives for overcoming health-related challenges in regional communities or for promoting health-conscious activities led by the Nippon Kenko Kaigi, and recognizes outstanding enterprises engaging in efforts for health and productivity management. The five criteria for selection in the recognition program for the large enterprise category are (i) the positioning of health and productivity management in management philosophy and policies, (ii) organized frameworks established for tackling health and productivity management, (iii) specific systems established for ensuring health-conscious management as well as measures introduced for implementing them, (iv) measures established for assessing and improving health and productivity management, and (v) adherence to laws and regulations and risk management. This is the second year of the recognition program, and 541 companies were recognized as Outstanding Health and Productivity Management Organizations in the large enterprise category (White 500), along with 775 companies in the small-medium enterprise category.

Eisai's corporate philosophy is to give first thought to patients and their families and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. The maintenance and promotion of the health of employees, who are key stakeholders in the company, is an important element in actualizing this corporate philosophy, and Eisai will continue to foster initiatives for the implementation of health management in the future as well.


About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Feb 21, 2018 08:25 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech, HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Apr 20, 2018 17:50 HKT/SGT
Eisai to Present Latest Data on Perampanel and Rufinamide at Annual American Academy of Neurology Meeting
Apr 19, 2018 11:07 HKT/SGT
Eisai: World's First Bile Acid Transporter Inhibitor "GOOFICE 5mg Tablet" Launched in Japan
Apr 13, 2018 13:22 HKT/SGT
Eisai Enters Into Joint Research Agreement With the Broad Institute, Colorado State University, and University of Chicago
Apr 2, 2018 12:44 HKT/SGT
Eisai Submits Supplemental New Drug Application to U.S. FDA
Mar 28, 2018 18:33 HKT/SGT
Eisai and Nichi-Iko Pharmaceutical Enter Into Strategic Alliance Agreement
Mar 23, 2018 14:41 HKT/SGT
AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-alpha Monoclonal
Mar 23, 2018 13:40 HKT/SGT
Eisai: Anticancer Agent LENVIMA Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan
Mar 14, 2018 11:16 HKT/SGT
Eisai Launches Gastrointestinal Prokinetic Agent Cidine (Cinitapride Hydrogen Tartrate) in China
Mar 8, 2018 13:33 HKT/SGT
Eisai and Merck & Co. Enter Global Strategic Oncology Collaboration for LENVIMA
Mar 8, 2018 12:00 HKT/SGT
Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: